Published in Pharma Investments, Ventures and Law Weekly, July 18th, 2004
According to a study from the United States, "the current standard of care for the treatment of hepatitis C virus (HCV) infection is the use of interferon alfa-2a or alfa-2b, standard (IFN) or pegylated (PEG-IFN), in combination with ribavirin (RBV). PEG-IFN is now the most commonly used IFN formulation because of its less frequent dosing requirement and overall improved sustained virologic response (SVR) rates. Patient adherence to these combination treatment regimens, particularly patients who have genotype 1 infection, appears to be important for viral eradication and achievement of an SVR."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.